| Identification | More | [Name]
Cefminox | [CAS]
75481-73-1 | [Synonyms]
(6r-(6-alpha,7-alpha))-7-((((2-amino-2-carboxyethyl)thio)acetyl)amino)-7-methoxy-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid monosodium salt
(6r,7s)-7-(2-(((s)-2-amino-2-carboxyethyl)thio)acetamido)-7-methoxy-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
CEFMINOX
CEFMINOX SOUDIUM
5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2-amino-2-carboxyethyl)thio]acetyl]amino]-7-methoxy-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, sodium salt, [6R-[6α,7α,7(S*)]]-
5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[[(2S)-2-amino-2-carboxyethyl]thio]acetyl]amino]-7-methoxy-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, sodium salt, (6R,7S)-
Cefminox sodium salt
Meicelin
(6R,7S)-7-(2-(((S)-2-Amino-2-carboxyethyl)thio)acetamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid | [Molecular Formula]
C16H21N7O7S3 | [MDL Number]
MFCD07793340 | [Molecular Weight]
519.58 | [MOL File]
75481-73-1.mol |
| Questions And Answer | Back Directory | [Application]
It is mainly used for sepsis, tonsillitis, bronchitis, pneumonia, lung abscess, pyelonephritis, cystitis, cholecystitis, peritonitis, pelvic inflammatory disease, adnexitis, endometritis, and postoperative infections caused by sensitive bacteria. |
| Hazard Information | Back Directory | [Definition]
ChEBI:Cefminox is a second-generation cephamycin antibiotic having [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl and 2-{[(2S)-2-amino-2-carboxyethyl]sulfanyl}acetamido side-groups located respectively at positions 3 and 7beta of the cephem nucleus. A broad-spectrum bactericide, it is especially effective against Gram-negative and anaerobic bacteria. It is a cephamycin and a member of tetrazoles. It is a conjugate acid of a cefminox(1-). | [Antimicrobial activity]
A semisynthetic cephamycin. Activity is similar to that of
cefoxitin and cefotetan, but the activity against enterobacteria
and B. fragilis is somewhat better . C. difficile
is inhibited by 4–16 mg/L. It is stable to the common
β-lactamases of enterobacteria and Bacteroides spp.
A 15-min intravenous infusion of 1 g achieves a serum concentration
of 30 mg/L after 1 h. The plasma half-life is c. 2 h
and around 68% is protein bound.
Its safety profile and uses are similar to those of other
cephamycins. It is available in Japan. |
|
|